Pharmacist Intervention and Identification of Adverse Events Related to Treatment Efficacy in Cancer Chemotherapy to Improve Clinical Outcomes

Overview

Journal J Pharm Health Care Sci

Publisher Biomed Central

Specialty Pharmacology

Date 2024 Dec 19

PMID 39696667

Authors

Hironori Fujii

Affiliations

Soon will be listed here.

Abstract

Adverse events (AEs) induced by cancer chemotherapy reduce not only patient quality of life (QOL) but also the efficacy of treatment. Management of AEs can therefore improve both the efficacy and safety of cancer chemotherapy. This review describes the contribution of pharmacists to the management of adverse events aimed at improving the treatment efficacy of cancer chemotherapy. Efforts to improve the evidence-practice gap are a useful approach to countermeasures against AEs. Pharmacists can intervene in these efforts in the course of their daily practice. Here, we made undertook to improve the evidence-practice gap in prophylaxis pharmacotherapy for chemotherapy-induced nausea and vomiting (CINV) and anti-EGFR antibody-induced acneiform rash. After intervention by pharmacists, the rate of adherence to prophylaxis pharmacotherapy for these AEs was significantly improved, and the incidence of CINV and acneiform rash was significantly decreased. Notably, time to treatment failure (TTF) with anti-EGFR antibody therapy tended to be increased, and may have contributed to an improvement in therapeutic effect. Next, we examined adverse events associated with anti-cancer drugs related to the therapeutic effect of cancer chemotherapy. Incidence of hypomagnesemia in patients receiving anti-EGFR antibodies and neutropenia in patients receiving TAS-102 was significantly associated with the therapeutic effect of cancer chemotherapy. Moreover, we examined the impact of cancer cachexia, a cancer-associated AE, on the therapeutic effect of immune checkpoint inhibitors. In patients receiving nivolumab, the presence of cancer cachexia prior to treatment initiation was associated with shorter OS and TTF. In summary, pharmacist management of AEs was shown to improve treatment response. Further, AEs which are predictive of treatment response in cancer chemotherapy were identified. Management of these AEs is an important role for pharmacists aiming to improve patient QOL and treatment efficacy.

References

Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K . Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol. 2020; 26(1):1-17. PMC: 7788035. DOI: 10.1007/s10147-020-01818-3. View

Roch B, Coffy A, Jean-Baptiste S, Palaysi E, Daures J, Pujol J . Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer. 2020; 143:19-26. DOI: 10.1016/j.lungcan.2020.03.003. View

Tan B, Fearon K . Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008; 11(4):400-7. DOI: 10.1097/MCO.0b013e328300ecc1. View

Fujii H, Koda M, Sadaka S, Ohata K, Kato-Hayashi H, Iihara H . Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy - a retrospective observational study. J Pharm Health Care Sci. 2021; 7(1):27. PMC: 8327438. DOI: 10.1186/s40780-021-00210-1. View

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B . Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25(13):1658-64. DOI: 10.1200/JCO.2006.08.1620. View

Fujii H, Makiyama A, Iihara H, Okumura N, Yamamoto S, Imai T . Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer. Anticancer Res. 2020; 40(12):7067-7075. DOI: 10.21873/anticanres.14734. View

Fujii H, Iihara H, Ishihara M, Takahashi T, Yoshida K, Itoh Y . Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk. Anticancer Res. 2013; 33(12):5549-56. View

Pfeiffer P, Yilmaz M, Moller S, Zitnjak D, Krogh M, Petersen L . TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020; 21(3):412-420. DOI: 10.1016/S1470-2045(19)30827-7. View

Pander J, Heusinkveld M, der Straaten T, Jordanova E, Baak-Pablo R, Gelderblom H . Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res. 2011; 17(17):5668-73. DOI: 10.1158/1078-0432.CCR-11-0239. View

10.

Sackett D, Rosenberg W, Gray J, Haynes R, Richardson W . Evidence based medicine: what it is and what it isn't. BMJ. 1996; 312(7023):71-2. PMC: 2349778. DOI: 10.1136/bmj.312.7023.71. View

11.

Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D . The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012; 23(8):1986-1992. DOI: 10.1093/annonc/mds021. View

12.

Haynes R, Devereaux P, Guyatt G . Clinical expertise in the era of evidence-based medicine and patient choice. ACP J Club. 2002; 136(2):A11-4. View

13.

Chan A, Low X, Yap K . Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. J Manag Care Pharm. 2012; 18(5):385-94. PMC: 10438054. DOI: 10.18553/jmcp.2012.18.5.385. View

14.

Hirose C, Fujii H, Iihara H, Ishihara M, Nawa-Nishigaki M, Kato-Hayashi H . Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy. Support Care Cancer. 2020; 28(12):5943-5952. PMC: 7686000. DOI: 10.1007/s00520-020-05443-8. View

15.

Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H . Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. Oncologist. 2020; 25(3):e469-e476. PMC: 7066722. DOI: 10.1634/theoncologist.2019-0541. View

16.

Bloechl-Daum B, Deuson R, Mavros P, Hansen M, Herrstedt J . Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006; 24(27):4472-8. DOI: 10.1200/JCO.2006.05.6382. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

Limagne E, Thibaudin M, Nuttin L, Spill A, Derangere V, Fumet J . Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunol Res. 2019; 7(12):1958-1969. DOI: 10.1158/2326-6066.CIR-19-0228. View

19.

Nose Y, Kagawa Y, Hata T, Mori R, Kawai K, Naito A . Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study. Cancer Chemother Pharmacol. 2020; 86(3):427-433. DOI: 10.1007/s00280-020-04129-6. View

20.

Hori K, Kobayashi N, Atsumi H, Nagayama A, Kondoh M, Noge I . Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network. Support Care Cancer. 2013; 22(4):969-77. DOI: 10.1007/s00520-013-2048-4. View